3billion
Financials
Valuation Metrics
3billion's Market Cap is ₩1900B. At end of 2025 it was ₩5801B. Ranked #851 of 2,436 in KR market (top 35%), #393 of 1,649 on KOSDAQ (top 24%), #92 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 39%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 189.98B KRW | KR#851/2,436 Sec#92/234 |
| Revenue | 13.07B KRW | KR#2,247/2,436 Sec#169/234 |
| Net Income | -5.17B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 28.29B KRW | KR#2,335/2,436 Sec#222/234 |
| Net Assets | 22.47B KRW | KR#2,248/2,436 Sec#209/234 |
| Employees | 85 | KR#1,753/2,436 Sec#141/234 |
| Value | ||
| P/B | 8.46x | KR#2,320/2,436 Sec#203/234 |
| P/S | 14.54x | KR#2,311/2,436 Sec#173/234 |
| FCF Yield | -3.08% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -23.02% | KR#2,109/2,436 Sec#166/234 |
| ROA | -18.28% | KR#2,215/2,436 Sec#173/234 |
| Op. Margin | -42.74% | KR#2,221/2,436 Sec#161/234 |
| Revenue Growth | 67.79% | KR#210/2,436 Sec#25/234 |
| Financial Health | ||
| Debt Ratio | 125.91% | KR#778/2,436 Sec#92/234 |
| Total Debt | 189.3M KRW | KR#2,016/2,436 Sec#193/234 |
| FCF | -5.85B KRW | KR#1,536/2,436 Sec#121/234 |
| Cash | 6.29B KRW | KR#1,901/2,436 Sec#167/234 |
| Current Ratio | 5.41x | KR#265/2,436 Sec#51/234 |
| Performance | ||
| 1Y Return | -10.36% | KR#978/2,436 Sec#72/234 |
| 1M Return | -6.13% | KR#1,486/2,436 Sec#148/234 |
| From 52W High | -70.30% | KR#2,145/2,436 Sec#194/234 |
| 1Y MDD | -75.59% | KR#2,172/2,436 Sec#198/234 |
| Trading | ||
| Volume | 249,462 shares | KR#476/2,436 Sec#47/234 |
| Foreign Own. | 14.15% | KR#334/2,436 Sec#25/234 |
| Per Share | ||
| EPS | -163 KRW | KR—/2,436 Sec—/234 |
| BPS | 707 KRW | KR#2,350/2,436 Sec#219/234 |
Company Info
3billion was established in 2016 to revolutionize rare disease diagnosis and treatment development using artificial intelligence, listing on KOSDAQ as a technology growth company in 2024. The company offers whole genome and whole exome-based rare disease diagnostic genetic testing services powered by AI genomic interpretation technology. By launching its genetic variant interpretation software 'GEBRA' as SaaS, 3billion is building an AI drug development platform based on accumulated data and expanding its technological competitiveness. 3billion is headquartered in Gangnam-gu, Seoul Metropolitan City.